Our newsroom provides you with the latest information about the German Breast Group. This section of the website also includes photographic material and information about our events. In addition, our Annual Scientific Reports, which provide an overview of our research activities, can be downloaded here.
We are delighted to inform you that results from a quality assurance process integrated into the INSEMA trial have been published in International Journal of Radiation Oncology, Biology, Physics.
Second Interim Analysis of Adjuvant Study for HR+, HER2- Early Breast Cancer demonstrates that there is little chance of palbociclib reducing the risk of recurrence
Data on several research projects from GBG and collaborative groups will be presented at the upcoming ASCO Virtual Meeting 2020, which will take place from 29 to 31 May 2020.
Data of several GBG research projects will be presented at the upcoming ESMO Breast Cancer Virtual Meeting 2020, which will take place from 23 to 24 May 2020.
A pooled analysis of nine prospective neoadjuvant breast cancer trials that aimed to identify independent predictors of Locoregional recurrence risk after neoadjuvant chemotherapy has been published in European Journal of Cancer.
A translational research project aiming to identify predictive markers for response to bevacizumab treatment in HER2-negative breast cancer from GeparQuinto study has been published in Clinical Cancer Research.
Information in order to treat the patients in the clinical study in the best possible way and in accordance with the protocol.
We are pleased to inform you that the surgical results of the randomized BrighTNess trial have been published in JAMA Surgery.
We are delighted to inform you that the long-term follow-up results of the randomized IBIS-II trial have been published in Lancet.
Results of a protocol-predefined secondary analysis from PANTHER trial have been published in Cancer.
A translational study evaluating the role of tumor immunogenicity in patients from GeparTrio trial has been published in Breast Cancer Research.
A meta-analysis of individual patient data from 12 randomized trials including 15,457 patients. Presented as SABCS 2019.
We are happy to present our contributions at the San Antonio Breast Cancer Symposium 2019.
A translational study investigating androgen receptor expression in breast cancer patients receiving neoadjuvant chemotherapy from the TECHNO and PREPARE trials has been published in the British Journal of Cancer.
Results of a secondary exploratory toxicity analysis investigating neutropenic complications in the phase III PANTHER trial of standard 3-weekly chemotherapy with FEC/D versus bi-weekly tailored dose-dense EC/D adjuvant chemotherapy in breast cancer have been published in the Acta Oncologica
Jenny Furlanetto, MD honoured with the Merit Award to the ESMO 2019 Congress
Results of a retrospective pooled analysis from three randomized neoadjuvant GBG trials (GeparTrio, GeparQuattro and GeparQuinto) evaluating the impact of post-mastectomy RT (PMRT) after NACT on survival in breast cancer patients have been published in the Annals of Surgical Oncology.
Data of GBG research projects were presented at ESMO 2019, September 27th to October 1st in Barcelona.
Data from two similar randomized phase III trials (LEA GBG51 and CALGB 40503) comparing the efficacy of standard ET versus experimental ET plus bevacizumab as first-line treatment for HR-positive MBC have been published in the European Journal of Cancer
The AGO State of the Art Meeting 2020 will take place 29th of February at the InterContinental Hotel, Wilhelm-Leuschner-Straße 43, 60329 Frankfurt. Please save the date!